8-K

                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934


         Date of Report (Date of earliest event reported): MAY 11, 2004
                                                           ------------

                             REPRO-MED SYSTEMS, INC.
             ------------------------------------------------------
             (Exact name of registrant as specified in its charter)


            NEW YORK                    0-12305               13-3044880
  ----------------------------      ---------------       -------------------
  (State or other jurisdiction      Commission File          (IRS Employer
       or incorporation)                Number)           Identification No.)


                      24 CARPENTER ROAD, CHESTER, NY 10918
          ------------------------------------------------------------
          (Address of principal executive offices, including zip code)


       Registrant's telephone number, including area code: (845) 469-2042
                                                           --------------

                                      N/A
          -------------------------------------------------------------
          (Former name or former address, if changed since last report)


ITEM 9. REGULATION FD DISCLOSURE

On May 11, 2004, the Registrant disseminated a press release. A copy of the
press release is attached as Exhibit 99.1.

                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.

                                        REPRO-MED SYSTEMS, INC.

Dated: May 11, 2004                     By:  /s/ Andrew I. Sealfon
                                        Its: President and
                                             Chief Executive Officer

EX-99

                                                                    EXHIBIT 99.1

Repro-Med Systems and Omni Biomed LLC Sign Distribution Agreement For Marketing
the Freedom60 Infusion System and the Res-Q-Vac Suction System

Tuesday May 11, 2004
:
Repro-Med Systems Inc., Chester, New York (OTC: REPR.OB) announced today a
distribution agreement with Omni Biomed based in Knoxville, Tennessee. Repro-Med
Systems develops and manufactures high performance, low cost medical devices.
Omni Biomed LLC services hospitals, physicians, clinics and home and long term
care markets in the South East United States. The agreement covers the Freedom60
Syringe Infusion System and the Res-Q-Vac Airway Suction System for the South
Eastern United States including Tennessee, Kentucky, Alabama, Arkansas, North
Carolina, South Carolina, Mississippi, Louisiana, West Virginia, Virginia,
Georgia, and Florida.

"It is with great excitement that we announce our agreement with Omni Biomed
which presents a unique opportunity in the infusion market for our Freedom60,"
comments Andy Sealfon, President of Repro-Med Systems, Inc. "Omni brings
together experience not only in distribution, but also operates their own
pharmacy and has direct user experience with the Freedom60 on patients. This
provides essential technical and financial knowledge of infusion delivery to
support their marketing. They already service hundreds of nursing homes and home
care centers in the South East, which will also facilitate introducing our
Res-Q-Vac to the home care market. " Sealfon added.

Ron Sherrill, President of Omni Healthcare said "We are delighted to become a
distributor for Repro-Med products. Our customers have already had positive
results from the Freedom60. Adding the Res-Q-Vac will help us in developing new
markets as well as expanding existing markets."

Acceptance of the Freedom60 Syringe System has been accelerated in domestic and
global markets with documented applications for vancomycin and desferal. In
Europe, the Freedom60 has made great progress in treating pain via epidural
administration. Omni's staff of clinical pharmacists and nurses, will introduce
the Freedom60 to these cases in the United States.

Omni's presence in the home care and nursing home market will enable it to
introduce the Res-Q-Vac for patients needing routine suction at home or in long
term care-- or anyone requiring airway suction maintenance. The use of Res-Q-Vac
is expanding into home care and hospitals due to the addition of Full Stop
Protection, which prevents any infection or contamination from exiting the
system, thus protecting the health care professionals and the public at large.
Protection against the spread of disease is mandated by OSHA law and indicated
in the CDC guidelines. Hospitals have been encouraged to provide isolation for
the treatment of potentially infected patients such as those suspected having
SARS, tuberculosis, AIDS/HIV, etc., all of which can be safely and cost
effectively treated in isolation using the filtered Res-Q-Vac.

For more information call:
Repro-Med Systems, Inc.
Andrew Sealfon
800-624-9600 x 307
andy@repro-med.com
www.Repro-Med.com



STATEMENTS IN THIS NEWS RELEASE THAT RELATE TO MANAGEMENT'S EXPECTATIONS,
INTENTIONS OR BELIEFS CONCERNING FUTURE PLANS, EXPECTATIONS, EVENTS AND
PERFORMANCE ARE "FORWARD LOOKING" WITHIN THE MEANING OF THE FEDERAL SECURITIES
LAWS. THESE FORWARD-LOOKING STATEMENTS INCLUDE ASSUMPTIONS, BELIEFS AND OPINIONS
RELATING TO THE COMPANY'S BUSINESS AND GROWTH STRATEGY BASED UPON MANAGEMENT'S
INTERPRETATION AND ANALYSIS OF ITS OWN CONTRACTUAL AND LEGAL RIGHTS,
MANAGEMENT'S ABILITY TO SATISFY INDUSTRY AND CONSUMER NEEDS WITH ITS
TECHNOLOGIES, HEALTH-CARE INDUSTRY TRENDS, AND MANAGEMENT'S ABILITY TO
SUCCESSFULLY DEVELOP, IMPLEMENT, MARKET AND/OR SELL ITS NETWORK TRANSACTION
PROCESSING SERVICES, SOFTWARE PROGRAMS, CLINICAL AND FINANCIAL TRANSACTION
SERVICES, AND E-COMMERCE SYSTEMS TO ITS CLIENTELE. THE FORWARD-LOOKING
STATEMENTS HAVE BEEN MADE BASED UPON REPRESENTATIONS MADE REGARDING THE
ACQUISITIONS INVOLVING THE COMPANY, AVAILABLE DUE DILIGENCE AND ANALYSIS OF
THOSE ACQUISITIONS THAT HAS BEEN AND WILL BE PERFORMED BY THE COMPANY OVER THE
PAST SIX MONTHS, AND THE RESULTING ANALYSIS OF THE COMPANY'S PROSPECTS. ACTUAL
RESULTS COULD DIFFER MATERIALLY FROM THAT INDICATED IN OUR DUE DILIGENCE.
MANAGEMENT'S FORWARD-LOOKING STATEMENTS FURTHER ASSUME THAT THE COMPANY WILL BE
ABLE TO SUCCESSFULLY DEVELOP AND EXECUTE ON ITS STRATEGIC RELATIONSHIPS. MANY
KNOWN AND UNKNOWN RISKS, UNCERTAINTIES AND OTHER FACTORS, INCLUDING GENERAL
ECONOMIC CONDITIONS AND RISK FACTORS DETAILED FROM TIME TO TIME IN NEWS RELEASES
AND THE COMPANY'S FILINGS WITH THE SECURITIES AND EXCHANGE COMMISSION, MAY CAUSE
THESE FORWARD-LOOKING STATEMENTS TO BE INCORRECT IN WHOLE OR IN PART. THE
INVESTOR SHOULD REVIEW SUCH PUBLIC FILINGS TO GET A COMPREHENSIVE PICTURE AND
ANALYSIS OF ALL CONDITIONS AND CIRCUMSTANCES. THE COMPANY EXPRESSLY DISCLAIMS
ANY INTENT OR OBLIGATION TO UPDATE ANY FORWARD LOOKING STATEMENTS. ACTUAL
RESULTS OR EVENTS COULD DIFFER MATERIALLY FROM THOSE ANTICIPATED IN THE
FORWARD-LOOKING STATEMENTS DUE TO A VARIETY OF FACTORS SET OUT ABOVE, INCLUDING,
WITHOUT LIMITATION, INTEGRATION OF BUSINESS AND MANAGEMENT ASSOCIATED WITH THE
COMPANY'S BUSINESS RELATIONSHIPS AND ACQUISITIONS, ACCEPTANCE BY CUSTOMERS OF
THE COMPANY'S PRODUCTS, CHANGING TECHNOLOGY, COMPETITION IN THE HEALTH-CARE
MARKET, GOVERNMENT REGULATION OF HEALTH CARE, THE COMPANY'S LIMITED OPERATING
HISTORY, VARIOUS PROBLEMS THAT CAN ARISE IN THE CONTEXT OF A MERGER OF COMPANIES
IN THIS MANNER, GENERAL ECONOMIC CONDITIONS, AVAILABILITY OF CAPITAL AND OTHER
FACTORS.